This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

FDA to Blame for Mannkind Delay?

Stocks in this article: MNKD

SAN FRANCISCO, Calif. ( TheStreet) -- Mannkind (MNKD) said late Friday that U.S. drug regulators are extending the review of its inhaled insulin device because an inspection of a third-party manufacturing facility is not yet complete.

The U.S. Food and Drug Administration was expected to issue an approval decision on the Mannkind diabetes device, now known by the brand name Afrezza, on Jan. 16. But Friday, FDA officials informed Mannkind that an inspection of a manufacturing plant owned by Organon that makes the insulin used in the Afrezza device was not complete. Organon is a subsidiary of Merck (MRK).

Mannkind said it does not know how long the FDA's review of Afrezza will be delayed.

Mannkind investors -- both bulls and bears -- were anxiously awaiting the FDA's Jan 16 decision on Afrezza, so Friday's announcement is a bit of a letdown. Mannkind shares fell 5% to $7.60 in Friday's after-market trading session after finishing the regular session at $8.04.

The FDA delay is also somewhat of an embarrassment for Mannkind executives who have boldly predicted FDA approval of Afrezza on Jan. 16. Last week, CEO Al Mann and COO Hakan Edstrom gave separate media interviews expressing confidence that the FDA's review was essentially complete and that approval was coming.

Mannkind officials are presenting at the J.P. Morgan Healthcare Conference Tuesday. Investors will surely be asking why Mannkind didn't know that the FDA's inspection of its outside insulin supplier was not yet complete.

A person close to Mannkind told me Friday night that FDA inspectors, in fact, had already visited the Organon insulin plant, located in France, and no questions or concerns were raised, leading Mannkind to believe that the inspection was done. The company was therefore surprised Friday when FDA told them that inspectors needed to revisit the Organon plant to complete inspection on a part of the facility that was missed during the previous visit.

"The FDA messed up," said the person close to Mannkind, who asked to remain anonymous because the company doesn't want to anger the agency while the Afrezza review remains open.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs